Related Experiment Video
Updated: Jun 30, 2025

Using the E1A Minigene Tool to Study mRNA Splicing Changes
Published on: April 22, 2021
Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to
Carolyn M Jablonowski1, Waise Quarni1, Shivendra Singh1
1Department of Surgery, St Jude Children's Research Hospital, Memphis, United States.
Abstract:
Dysregulated pre-mRNA splicing and metabolism are two hallmarks of MYC-driven cancers. Pharmacological inhibition of both processes has been extensively investigated as potential therapeutic avenues in preclinical and clinical studies. However, how pre-mRNA splicing and metabolism are orchestrated in response to oncogenic stress and therapies is poorly understood. Here, we demonstrate that jumonji domain containing 6, arginine demethylase, and lysine hydroxylase, JMJD6, acts as a hub connecting splicing and metabolism in MYC-driven human neuroblastoma. JMJD6 cooperates with MYC in cellular transformation of murine neural crest cells by physically interacting with RNA binding proteins involved in pre-mRNA splicing and protein homeostasis. Notably, JMJD6 controls the alternative splicing of two isoforms of glutaminase (GLS), namely kidney-type glutaminase (KGA) and glutaminase C (GAC), which are rate-limiting enzymes of glutaminolysis in the central carbon metabolism in neuroblastoma. Further, we show that JMJD6 is correlated with the anti-cancer activity of indisulam, a 'molecular glue' that degrades splicing factor RBM39, which complexes with JMJD6. The indisulam-mediated cancer cell killing is at least partly dependent on the glutamine-related metabolic pathway mediated by JMJD6. Our findings reveal a cancer-promoting metabolic program is associated with alternative pre-mRNA splicing through JMJD6, providing a rationale to target JMJD6 as a therapeutic avenue for treating MYC-driven cancers.
Insights
JMJD6 connects pre-mRNA splicing and metabolism in MYC-driven cancers. Targeting JMJD6 may offer new therapies for neuroblastoma by impacting glutamine metabolism and splicing.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- MYC-driven cancers exhibit dysregulated pre-mRNA splicing and metabolism.
- Therapeutic strategies targeting these processes are under investigation.
- The interplay between splicing and metabolism under oncogenic stress remains unclear.
Purpose of the Study:
- To investigate the role of JMJD6 in connecting pre-mRNA splicing and metabolism in MYC-driven neuroblastoma.
- To elucidate how JMJD6 influences cellular transformation and metabolic pathways in response to oncogenic stress.
Main Methods:
- Investigated JMJD6 interactions with MYC and RNA-binding proteins.
- Analyzed JMJD6's control over glutaminase (GLS) alternative splicing.
- Assessed the correlation between JMJD6, indisulam, and cancer cell killing.
Main Results:
- JMJD6 acts as a hub linking splicing and metabolism in MYC-driven neuroblastoma.
- JMJD6 controls alternative splicing of kidney-type glutaminase (KGA) and glutaminase C (GAC) isoforms.
- JMJD6 is linked to the anti-cancer effects of indisulam, a drug targeting RBM39.
Conclusions:
- JMJD6 promotes a cancer-associated metabolic program linked to alternative pre-mRNA splicing.
- Targeting JMJD6 presents a potential therapeutic strategy for MYC-driven cancers, including neuroblastoma.
Related Concept Videos
RNA Splicing
Pre-mRNA Processing: RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
MicroRNAs
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...

